

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (20G11) Rabbit mAb

RRID:AB_331772

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4376, RRID:AB_331772

Antibody Information

URL: http://antibodyregistry.org/AB_331772

Proper Citation: Cell Signaling Technology Cat# 4376, RRID:AB_331772

Target Antigen: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P. Consolidation: AB_2315155.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (20G11) Rabbit mAb

Description: This monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

Target Organism: Human, Rat, Monkey, Zebrafish, Pig, Mouse, Mink, Hamster

Clone ID: 20G11

Defining Citation: [PMID:23720424](#), [PMID:24823391](#), [PMID:24437490](#), [PMID:19565663](#), [PMID:23525221](#)

Antibody ID: AB_331772

Vendor: Cell Signaling Technology

Catalog Number: 4376

Alternative Catalog Numbers: 4376S

Record Creation Time: 20250819T213515+0000

Record Last Update: 20250819T232632+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (20G11) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 113 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Diaz-Jimenez A, et al. (2026) EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis. Cancer discovery, 16(1), 46.

Anastacio Da Costa Carvalho L, et al. (2026) RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. Cancer immunology research, 14(1), 90.

Ageta-Ishihara N, et al. (2025) Septin 3 regulates memory and L-LTP-dependent extension of endoplasmic reticulum into spines. Cell reports, 44(3), 115352.

Nakajima-Koyama M, et al. (2025) The balance between IFN- γ and ERK/MAPK signaling activities ensures lifelong maintenance of intestinal stem cells. Cell reports, 44(3), 115286.

Chávez LF, et al. (2025) GEF-H1 drives breast cancer cells to tumor progression. Biochimica et biophysica acta. Molecular basis of disease, 1871(5), 167816.

Hsu YC, et al. (2025) Overexpression of NR1D1 Portends Disease Recurrence in Thyroid Cancer. The Journal of clinical endocrinology and metabolism, 110(4), 991.

Wang Y, et al. (2025) Innate immune and metabolic signals induce mitochondria-dependent membrane lysis via mitoxperiosis. Cell, 188(25), 7155.

Chronis IB, et al. (2025) The α_2 adrenergic receptor cross-linked interactome identifies 14-3-3 proteins as regulating the availability of signaling-competent receptors. *Molecular pharmacology*, 107(1), 100005.

Lubosch A, et al. (2025) The immune response against cancer is modulated by stromal cell fibronectin. *Neoplasia* (New York, N.Y.), 67, 101196.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. *Cell reports*, 44(4), 115541.

Ikeda T, et al. (2025) HUWE1 stimulates mTORC1 activity by enhancing Rheb interaction with mTORC1 and supports de novo pyrimidine synthesis. *Cell reports*, 44(10), 116382.

Saito H, et al. (2025) Immunohistochemical distribution of extracellular signal-regulated kinase 1 and 2 (ERK1/2) in the rat carotid body. *Tissue & cell*, 99, 103247.

Mozzarelli AM, et al. (2025) RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma. *Cancer research*, 85(17), 3196.

Wang R, et al. (2024) H3K9 lactylation in malignant cells facilitates CD8⁺ T cell dysfunction and poor immunotherapy response. *Cell reports*, 43(9), 114686.

Chang Y, et al. (2024) The UBE2F-CRL5ASB11-DIRAS2 axis is an oncogene and tumor suppressor cascade in pancreatic cancer cells. *Developmental cell*, 59(10), 1317.

Francis JW, et al. (2024) FAM86A methylation of eEF2 links mRNA translation elongation to tumorigenesis. *Molecular cell*.

Li GX, et al. (2024) Comprehensive proteogenomic characterization of rare kidney tumors. *Cell reports. Medicine*, 5(5), 101547.

Palanivel V, et al. (2024) Neuropeptide Y receptor activation preserves inner retinal integrity through PI3K/Akt signaling in a glaucoma mouse model. *PNAS nexus*, 3(8), pgae299.

Giangreco G, et al. (2024) Cancer cell - Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma. *iScience*, 27(9), 110635.

Ivovic A, et al. (2024) β -Cell Insulin Resistance Plays a Causal Role in Fat-Induced β -Cell Dysfunction In Vitro and In Vivo. *Endocrinology*, 165(5).